“Hybrid economics” is indeed what Wheeler said. This means that, in the case of an authorized generic, the economics for MNTA are based on a formula that’s a hybrid of the formula used for a sole generic and the formula used for multiple generics. The existence of a hybrid formula for the AG scenario is old news.